Policy Developments - The National Healthcare Security Administration issued the "Guidelines for the Establishment of Pricing Projects for Physical Therapy Medical Services (Trial)" which integrates existing pricing projects into 32 items, with 7 additional charges and 1 expansion item [2] Medical Device Approvals - In July, the National Medical Products Administration approved 295 medical device products, including 240 domestic Class III devices, 21 imported Class III devices, 29 imported Class II devices, and 5 devices from Hong Kong, Macau, and Taiwan [4] Company Announcements - New Industries announced that 18 of its chemiluminescent reagent products received IVDR CE certification, allowing them to enter the EU market, which is expected to enhance the company's competitiveness [5] - Jining Pharmaceutical received a drug re-registration approval for hydrolyzed protein injection, which is used for severe amino acid deficiency and will help restore normal production and sales [6] - Chongqing Pharmaceutical Holdings reported a net profit of 282 million yuan for the first half of the year, with a revenue of 41.188 billion yuan, marking a 3.54% year-on-year increase [8] - Jimin Health reported a net loss of 52.6959 million yuan for the first half of 2025, with a revenue of 36.6 million yuan, down 21.30% year-on-year [9] - Chenguang Bio announced plans to transfer 97.5% of its subsidiary Chenguang Tianrun Pharmaceutical to Sichuan Tongsheng Biomedical, with the transfer based on the subsidiary's equity as of July 31, 2025 [11] - Baiyang Pharmaceutical's controlling shareholder plans to increase capital and change the shareholding structure, with a new entity set to acquire 80% of the controlling group [13] Industry Events - A groundbreaking cervical spine surgery was successfully performed in Shanghai, utilizing innovative "satellite steel plate" technology to stabilize a severely injured patient's spine [15] - Guangxi plans to provide free HPV vaccinations to nearly 960,000 eligible girls from 2025 to 2027, emphasizing the importance of preventive healthcare [16] Shareholder Actions - Multiple shareholders of Sanxin Medical plan to reduce their stakes in the company due to personal financial needs, with specific share amounts outlined for each individual [18]

晨光生物公告，全资子公司河北晨光药业拟以晨光天润制药截至2025年7月31日的账面股东权益为准将 持有的晨光天润制药97.5%股权转让给四川同晟生物医药有限公司。转让完成后，晨光天润制药将不再 纳入公司合并报表范围。截至2025年7月31日，公司（含其他子公司）向晨光天润制药提供借款余额为 7078.24万元。 ...

关于拟转让控股子公司股权暨被动形成财务资助的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 证券代码：300138 证券简称：晨光生物 公告编号：2025—073 晨光生物科技集团股份有限公司 一、交易概述 1、晨光生物科技集团股份有限公司（以下简称"公司"或"晨光生物"） 全资子公司——河北晨光药业有限公司（以下简称"晨光药业"）持有河北晨光 天润制药有限公司（以下简称"晨光天润制药"）97.5%股权。 为优化资产结构，晨光药业拟以晨光天润制药截至 2025 年 7 月 31 日的账面 股东权益为准将持有的晨光天润制药 97.5%股权转让给四川同晟生物医药有限 公司（"同晟医药"）。本次股权转让完成后，晨光天润制药公司将不再是公司 合并报表范围内的子公司。 2025 年 8 月 18 日，晨光药业、晨光天润制药、同晟医药、公司实际控制人 卢庆国及同晟医药控股股东的关联人陈云虎签署了《股权转让协议》，《股权转 让协议》须经公司有权决策机构批准后生效。 2、本次转让事项不构成关联交易，也不构成《上市公司重大资产重组管理 办法》规定的重大资产重组。本次转让股 ...

| 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | 成交额(元) | | --- | --- | --- | --- | --- | --- | | 600737 | 中粮糖业 | 12.62 | 10.03% | 76.42万 | 9.50亿 | | 000911 | 广农糖业 | 7.85 | 2.35% | 26.59万 | 2.11亿 | | 000930 | 中粮科技 | 6.10 | 0.66% | 53.91万 | 3.33亿 | | 666000E | 全龙鱼 | 31.72 | 0.60% | 32.10万 | 10.28亿 | | 300268 | *ST佳沃 | 10.45 | 0.58% | 1.98万 | 2084.26万 | | 000972 | *ST中基 | 3.62 | 0.28% | 18.55万 | 6700.65万 | | 600191 | 华资实业 | 8.00 | 0.25% | 12.21万 | 9862.28万 | | 300138 | 晨光生物 | 13.60 | 0.15% | 8.47万 | 1.15 Z | | 605198 | 安德利 | ...

人民财讯8月14日电，晨光生物（300138）8月14日在互动平台表示，公司在2019年即开始布局工业大麻 业务，目前已在云南腾冲建成专门的生产基地，并取得《工业大麻种植许可证》和《工业大麻加工许可 证》，具备合法种植、提取、加工、销售全流程资质。公司工业大麻提取物产品有高纯度CBD晶体 (99%)、全谱CBD油(50%)等多种规格，目前工业大麻业务处于发展初期，其收入占公司总营收比重在 0.1%以下。公司正密切关注国内外相关政策，若下游需求增加，可依托规模化生产能力和显著成本领 先优势，抢占市场增量。 ...

证券日报网讯晨光生物（300138）8月12日在互动平台回答投资者提问时表示，新疆是公司重要的原材 料产区之一，新藏铁路建设有利于新疆经济发展及区域稳定，为公司经营业务开展创造优质环境。 ...

证券日报网讯晨光生物（300138）8月12日在互动平台回答投资者提问时表示，公司在植物有效成分提 取、分离、纯化方面拥有成熟的技术平台，具备对红薯叶中黄酮、多酚等潜在抗癌活性成分进行提取、 分离及纯化的能力。 ...

Core Viewpoint - The industrial hemp sector experienced a significant surge on December 12, driven by news that former President Trump is considering reclassifying marijuana's danger level, which could lower its regulatory status [1] Market Performance - Fu'an Pharmaceutical rose over 15% - Rhine Biology hit the daily limit up - Morning Light Bio increased nearly 7% - Kang En Bei and Fu Ri Electronics both rose around 6% [1] U.S. Market Reaction - U.S. cannabis stocks saw strong performance on Monday: - Canopy Growth surged over 26% - Tilray Brands jumped over 40% - Cronos Group increased by more than 14%, reaching a 52-week high [1] Industrial Hemp Overview - Industrial hemp is characterized by a tetrahydrocannabinol (THC) content of less than 0.3% and does not exhibit psychoactive effects - Its seeds, flowers, leaves, stalks, and roots can be utilized in textiles, food, daily chemicals, and pharmaceuticals [1] Market Growth Forecast - According to Mordor Intelligence, the global industrial hemp market is projected to grow from $2.21 billion in 2023 to $4.97 billion by 2028 - This represents a compound annual growth rate (CAGR) of 17.56% over the next five years [1]

格隆汇8月12日｜A股市场工业大麻概念股集体上涨，其中，福安药业(300194)涨15%，莱茵生物 (002166)10CM涨停，晨光生物(300138)涨超6%，德展健康(000813)涨超4%，顺灏股份(002565)、康恩贝 (600572)涨超3%。 | 代码 | 名称 | | 涨幅% ↓ | 总市值 | 年初至今涨幅%。 | | --- | --- | --- | --- | --- | --- | | 300194 | 福安药业 | 1 | 15.02 | 63.77 乙 | 21.65 | | 002166 | 菜菌生物 | | 10.05 | 68.23亿 | 24.71 | | 300138 | 晨光生物 | alc | 6.38 | 69.32亿 | 66.51 | | 000813 | 德展健康 | 1 | 4.39 | 94.79亿 | 44.41 | | 002565 | 顺灏股份 | | 3.65 | 90.42亿 | 182.80 | | 600572 | 康恩贝 | | 3.25 | 120亿 | 5.90 | | 002303 | 美盈森 | | 1.90 | 65.85 Z ...

（编辑 任世碧） 证券日报网讯 8月11日晚间，晨光生物发布公告称，公司及子公司累计决议对合并报表范围内主体融资 担保总额为250，000万元，占公司最近一期经审计净资产的80.40%，其中：已签订协议担保额度为 108，725万元（本次担保情况变动前，已签订协议担保余额为113，725万元）。公司及子公司无逾期对 外担保情况。 ...